Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(04): 241-246
DOI: 10.1590/0004-282X20180012
Article

OxLDL plasma levels in patients with Alzheimer's disease

Níveis plasmáticos de LDL-ox em pacientes com doença de Alzheimer
Marina Felipe Grossi
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
,
Maria das Graças Carvalho
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
,
Josianne Nicácio Silveira
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
,
Gisele Santos Gonçalves
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
2   Centro Universitário Newton Paiva, Belo Horizonte MG, Brasil
,
Karina Braga Gomes
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
,
Maria Aparecida Bicalho
3   Universidade Federal de Minas Gerais, Hospital das Clínicas, Instituto Jenny de Andrade Faria, Ambulatório de Idosos, Belo Horizonte MG, Brasil
4   Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Belo Horizonte MG, Brasil
,
Ieda de Fátima Oliveira Silva
1   Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil
› Author Affiliations
› Further Information
Also available at
  Permissions and Reprints

ABSTRACT

Objective: The objective of this study was to characterize the conventional lipid profile, oxLDL levels and ApoE polymorphism in patients with Alzheimer's disease (AD) and in elderly individuals without cognitive impairment.

Methods: Eighty elderly individuals were selected and the levels of oxLDL were determined using the ELISA kit, and ApoE gene polymorphism was investigated using polymerase chain reaction-restriction fragment length polymorphism.

Results: Significantly reduced levels of oxLDL were observed in patients with AD compared to the control group. A higher frequency of the ApoE ε4 allele was observed in patients with AD compared to controls. No difference was observed for total cholesterol, HDL-C, and LDL-C levels between the two groups, while triglyceride levels were higher in controls compared with patients with AD.

Conclusion: The data analyzed together did not reveal significant differences in lipid profiles, including oxLDL levels. However, the importance of lipid changes in the genesis of the disease cannot be ruled out. Nevertheless, the ApoE ε4 allele was significantly more frequent in patients with Alzheimer's dementia in agreement with previous findings in the literature, but this genetic component did not change the levels of oxLDL.

RESUMO

Objetivo: O objetivo deste estudo foi caracterizar o perfil lipídico convencional, os níveis de LDL-ox e o polimorfismo da ApoE em pacientes com doença de Alzheimer (DA) e em indivíduos idosos sem comprometimento cognitivo.

Métodos: Foram selecionados oitenta indivíduos idosos. Os níveis de LDL-ox foram determinados usando o kit ELISA e a investigação do polimorfismo do gene da ApoE por PCR-RFLP.

Resultados: Níveis significativamente reduzidos de LDL-ox foram observados em pacientes com DA comparado ao grupo controle. Uma maior frequência do alelo ε4 da ApoE foi observada nos pacientes com DA em relação aos controles. Nenhuma diferença foi observada para os níveis de colesterol total, HDL-C e LDL-C entre os dois grupos, enquanto níveis de triglicérides foram mais altos em controles comparados aos pacientes com DA.

Conclusão: Os dados analisados em conjunto não revelaram diferenças significativas no perfil lipídico, incluindo os níveis de LDL-ox. No entanto, não se pode excluir a importância de alterações lipídicas na gênese da doença. Não obstante, o alelo ε4 da ApoE foi signicativamente mais frequente nos pacientes com demência de Alzheimer em concordância com achados prévios da literatura, mas esse componente genético não interferiu nos níveis de LDL-ox.

Keywords:

Alzheimer's disease - Cholesterol - LDL

Palavras-chave:

Doença de Alzheimer - LDL-colesterol

Support

FAPEMIG (Fundação de Amparo à Pesquisa de Minas Gerais) and CNPq (Conselho Nacional do Desenvolvimento da Pesquisa).




Publication History

Received: 13 July 2017

Accepted: 17 December 2017

Article published online:
28 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001 Oct;57(8):1447-52. https://doi.org/10.1212/WNL.57.8.1447
  • 2 Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol. 2015 Apr;38(4):243-50. https://doi.org/10.1002/clc.22361
  • 3 Escargueil-Blanc I, Salvayre R, Nègre-Salvayre A. Necrosis and apoptosis induced by oxidized low density lipoproteins occur through two calcium-dependent pathways in lymphoblastoid cells. FASEB J. 1994 Oct;8(13):1075-80.
  • 4 Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem. 2010 Feb;43(3):267-71. https://doi.org/10.1016/j.clinbiochem.2009.08.021
  • 5 Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer's disease. Biomed Rep. 2016 May;4(5):519-22. https://doi.org/10.3892/br.2016.630
  • 6 Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:ID152786. https://doi.org/10.1155/2013/152786
  • 7 Tsai NW, Lee LH, Huang CR, Chang WN, Chang YT, Su YJ et al. Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care. 2014 Jan;18:R16. https://doi.org/10.1186/cc13695
  • 8 Munoz DG, Feldman H. Causes of Alzheimer's disease. CMAJ. 2000 Jan;162(1):65-72.
  • 9 Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003 Mar;84(6):1215-36. https://doi.org/10.1046/j.1471-4159.2003.01615.x
  • 10 Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci. 2013 Nov;5:64. https://doi.org/10.3389/fnagi.2013.00064
  • 11 Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF; The National Institute of Mental Health Genetics Initiative. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. Arch Neurol. 1994 Dec;51(12):1198-204. https://doi.org/10.1001/archneur.1994.00540240042014
  • 12 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. https://doi.org/10.1016/0022-3956(75)90026-6
  • 13 Almeida OP, Almeida SA. [Reliability of the Brazilian version of the Geriatric Depression Scale (GDS) short form]. Arq Neuropsiquiatr. 1999 Jun;57 2B:421-6. Portuguese. https://doi.org/10.1590/S0004-282X1999000300013
  • 14 Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323-9. https://doi.org/10.1093/geronj/37.3.323
  • 15 Camozzato AL, Godinho C, Kochhann R, Massochini G, Chaves ML. Validity of the Brazilian version of the Neuropsychiatric Inventory Questionnaire (NPI-Q). Arq Neuropsiquiatr. 2015 Jan;73(1):41-5.https://doi.org/10.1590/0004-282X20140177
  • 16 Montaño MB, Ramos LR. Validity of the Portuguese version of clinical dementia rating. Rev Saude Publica. 2005 Dec;39(6):912-7. https://doi.org/10.1590/S0034-89102005000600007
  • 17 Mattis S. Dementia rating scale: professional manual. Florida: Psychological Assessment Resources; 1988.
  • 18 Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med. 1993 Apr;121(4):598-602.
  • 19 Sinem F, Dildar K, Gökhan E, Melda B, Orhan Y, Filiz M. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res. 2010 Aug;7(5):463-9. https://doi.org/10.2174/156720510791383822
  • 20 Yamchuen P, Aimjongjun S, Limpeanchob N. Oxidized low density lipoprotein increases acetylcholinesterase activity correlating with reactive oxygen species production. Neurochem Int. 2014 Dec;78:1-6. https://doi.org/10.1016/j.neuint.2014.07.007
  • 21 Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012 Apr;134(1):8-25. https://doi.org/10.1016/j.pharmthera.2011.12.002
  • 22 Tong XK, Lecrux C, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci. 2012 Apr;32(14):4705-15. https://doi.org/10.1523/JNEUROSCI.0169-12.2012
  • 23 Cacabelos R. Pharmacogenomics in Alzheimer's disease. Methods Mol Biol. 2008;448:213-357. https://doi.org/10.1007/978-1-59745-205-2_10
  • 24 Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, Harskamp F et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997 Jan;349(9046):151-4. https://doi.org/10.1016/S0140-6736(96)09328-2
  • 25 Zhu H, Bhadelia RA, Liu Z, Vu L, Li H, Scott T et al. The association between small vessel infarcts and the activities of amyloid-β peptide degrading proteases in apolipoprotein E4 allele carriers. Angiology. 2013 Nov;64(8):614-20. https://doi.org/10.1177/0003319712462125
  • 26 Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain. 2012 Jul;135(Pt 7):2155-68. https://doi.org/10.1093/brain/aws127